Viva Biotech (Shanghai) Ltd.

Viva Biotech is a publicly traded company (01873.HK) and its investment decisions for the EFS (equity-for-service) business are made by its management team. The firm does not publicly name a single CIO or investment head for the EFS portfolio. Corporate governance is overseen by a board of directors as disclosed in its Hong Kong Stock Exchange filings.

Viva's EFS model generates deal flow from its existing CRO client base. As clients engage Viva for drug discovery services, the firm identifies high-potential startups and offers service contracts in exchange for equity stakes. This creates a captive pipeline of companies that are already using Viva's platforms.

Viva Biotech is a publicly listed company (01873.HK) operating as a contract research and manufacturing organization. It does not function as a family office. Its EFS business functions more like a venture investment arm within a corporate structure, distinct from pooled investment vehicles.

Viva's EFS investments target early-stage biotech startups — typically those still in preclinical discovery or requiring platform services such as protein expression, structure determination, or hit identification. The firm does not disclose specific stage or ticket-size ranges publicly.

Viva Biotech engages exclusively through direct equity stakes in portfolio companies via its EFS model. There is no public disclosure of any fund-of-funds or external GP commitment activity. The firm's investment activity is tied directly to its service relationships.

Viva Biotech focuses entirely on biotech and pharmaceutical drug discovery. It does not publicly disclose any excluded sectors, but its operating model — rooted in structure-based drug discovery — implies a focus on small-molecule and biologics therapeutics.

Langhua Pharma is a wholly owned subsidiary of Viva Biotech that provides CMC (Chemistry, Manufacturing, and Control) services. It handles the manufacturing and commercial-scale production stage, extending Viva's one-stop offering from early discovery to commercial drug delivery.